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Data from emergency medicine palliative
care access (EMPallA): a randomized
controlled trial comparing the effectiveness
of specialty outpatient versus telephonic
palliative care of older adults with advanced
illness presenting to the emergency
department
Abigail M. Schmucker1, Mara Flannery2*, Jeanne Cho2, Keith S. Goldfeld3, Corita Grudzen2,3 and The EMPallA
Investigators

Abstract
Background: The Emergency Medicine Palliative Care Access (EMPallA) trial is a large, multicenter, parallel, two-arm
randomized controlled trial in emergency department (ED) patients comparing two models of palliative care: nurseled telephonic case management and specialty, outpatient palliative care. This report aims to: 1) report baseline
demographic and quality of life (QOL) data for the EMPallA cohort, 2) identify the association between illness type
and baseline QOL while controlling for other factors, and 3) explore baseline relationships between illness type,
symptom burden, and loneliness.
Methods: Patients aged 50+ years with advanced cancer (metastatic solid tumor) or end-stage organ failure (New York
Heart Association Class III or IV heart failure, end stage renal disease with glomerular filtration rate < 15 mL/min/m2, or Global
Initiative for Chronic Obstructive Lung Disease Stage III, IV, or oxygen-dependent chronic obstructive pulmonary disease
defined as FEV1 < 50%) are eligible for enrollment. Baseline data includes self-reported demographics, QOL measured by the
Functional Assessment of Cancer Therapy-General (FACT-G), loneliness measured by the Three-Item UCLA Loneliness Scale,
and symptom burden measured by the Edmonton Revised Symptom Assessment Scale. Descriptive statistics were used to
analyze demographic variables, a linear regression model measured the importance of illness type in predicting QOL, and
chi-square tests of independence were used to quantify relationships between illness type, symptom burden, and loneliness.
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Results: Between April 2018 and April 3, 2020, 500 patients were enrolled. On average, end-stage organ failure patients had
lower QOL as measured by the FACT-G scale than cancer patients with an estimated difference of 9.6 points (95% CI: 5.9,
13.3), and patients with multiple conditions had a further reduction of 7.4 points (95% CI: 2.4, 12.5), when adjusting for age,
education level, race, sex, immigrant status, presence of a caregiver, and hospital setting. Symptom burden and loneliness
were greater in end-stage organ failure than in cancer.
Conclusions: The EMPallA trial is enrolling a diverse sample of ED patients. Differences by illness type in QOL, symptom
burden, and loneliness demonstrate how distinct disease trajectories manifest in the ED.
Trial registration: Clinicaltrials.gov identifier: NCT03325985. Registered October 30, 2017.
Keywords: Palliative care, Randomized controlled trial, Geriatrics, Advanced cancer, End-stage organ failure, Functional
decline, Patient-reported outcomes, Quality of life

Background
Emergency departments are frequently visited by severely ill patients approaching the end of life; in a study
of older adults who died between 1992 and 2006, 75%
visited the emergency department during the last six
months of life [1]. Although the focus of emergency
medicine has traditionally been the diagnosis and treatment of acute illnesses and injuries, emergency clinicians
have identified a growing need for palliative care interventions in the emergency setting to address the symptoms and stresses of advanced chronic illnesses [2, 3].
Palliative care is defined by the World Health Organization
as “an approach that improves the quality of life (QOL) of
patients and their families facing the problems associated
with life-threatening illness, through the prevention and relief
of suffering by means of early identification and impeccable
assessment and treatment of pain and other problems, physical, psychosocial, and spiritual.” [4] Palliative care has been
shown to improve patients’ symptoms and QOL across a
broad range of serious, life-limiting illnesses. Patients receiving palliative care are often able to remain cared for and supported at home, resulting in greater patient and family
satisfaction and less prolonged grief and post-traumatic stress
disorder among bereaved family members [5–10]. Palliative
care also decreases healthcare-related costs by reducing unnecessary hospitalizations, interventions, and avoidable ED
and intensive care [11–15].
In cancer patients, randomized controlled trials of palliative care interventions have shown better QOL and
mood, as well as improved symptom management and
patient satisfaction, with palliative care in addition to
standard care [12, 16]. Palliative care has its roots in the
care of cancer patients at the end of life, but increasing
studies support its potential to benefit patients with endstage organ failure, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF) and
end-stage renal disease (ESRD), which can also cause
physical, psychosocial, and spiritual distress [17, 18].
While both cancer and end-stage organ failure patients
stand to benefit from palliative care, the illness trajectories

associated with advanced cancer differ from those of organ
failure [19]. Cancer patients commonly have a short period of
evident decline before death; however, patients with endstage organ failure have a pattern of long-term decline with
episodes of worsening and remission [18]. Efforts to integrate
palliative care screening and assessment into the emergency
department have yielded positive outcomes, yet further research is needed to identify specific effective interventions
[20]. Understanding aspects of patients’ experiences of advanced chronic diseases, such as quality of life and symptom
burden, at the time of their presentation to the emergency
department could assist emergency providers as they develop
patient-centered treatment plans. We are not aware
of any literature describing how the distinct trajectories of advanced cancer and end-stage organ failure
patients manifest in the ED.
This paper reports on a large, multicenter, parallel,
two-arm randomized controlled trial in ED patients
comparing two established models of palliative care:
nurse-led telephonic case management and specialty,
outpatient palliative care. The objectives of this paper
are to: 1) report preliminary baseline demographic and
QOL data for the EMPallA trial cohort, 2) identify the
association between illness type and baseline QOL while
controlling for other baseline factors, and 3) explore the
baseline relationships between illness type, symptom
burden, and loneliness.

Methods
Study design

The Emergency Medicine Palliative Care Access (EMPallA)
trial was approved by the Institutional Review Boards (IRBs)
across all study sites. This study is funded through the
Patient-Centered Outcomes Research Institute (PCORI). We
registered this randomized controlled trial (RCT) in the
international trial register (ClinicalTrials.gov: Identifier
NCT03325985). This study adheres to Consolidated Standards of Reporting Trials (CONSORT) guidelines. See Supplement 1 for CONSORT checklist. For further details
please refer to our protocol paper [21].
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Study setting and population

Measures

This RCT began recruitment in April 2018 and is currently enrolling at 18 emergency department (ED) sites
across the United States (US), with locations representing the geographic diversity of the country. Patients considered for enrollment in this study comprise adults
aged 50 years or older, who have advanced cancer (metastatic solid tumor) or end-stage organ failure (New York
Heart Association class III or IV heart failure, end stage
renal disease with glomerular filtration rate < 15 mL/
min/m2 or on dialysis, or global initiative for chronic
obstructive lung disease stage III, IV or oxygendependent), reside within the geographical area, have a
working telephone, and have health insurance. Exclusion
criteria include not speaking English or Spanish, having
dementia documented in the electronic health record
(EHR) problem list, having received hospice services or
two or more palliative care visits in the last six months,
residing in a long-term care facility, or being admitted to
the hospital for more than 48 h post ED encounter.

Research assistants collect primary and secondary outcome data as well as demographic variables via face-toface bedside interview or EHR at baseline. Demographic
data include sex, race, ethnicity, income, education, religion, marital status, insurance, birth country, residency
type, and language.
The primary study outcome is change in patient QOL
from enrollment to six months, as measured by the
Functional Assessment of Cancer Therapy-General
(FACT-G, Version 4). QOL is a well-established outcome measure in palliative care research, [24, 25] and
the FACT-G has been validated and used extensively to
assess chronic disease therapy in many serious illnesses
[24]. It has 28 items in a five-point Likert scoring scale
from “0” (Not at all) to “4” (Very much) which assess
QOL across four domains: physical, social/family, emotional, and functional. We followed the standard FACTG Version 4 scoring algorithm to obtain both subscale
and total FACT-G scores. We broke down FACT-G
scores by domain to obtain a subscale score (possible
range 0–28 for physical, social/family, and functional; 0–
24 for emotional), and summed the subscale scores to
obtain an overall QOL score (possible range 0–108).
Higher FACT-G scores in each domain as well as overall
indicate better QOL.
Secondary outcomes in patients include loneliness, as
measured by change in Three-Item UCLA Loneliness
Scale from enrollment to 6 months [26, 27]; and symptom burden, as measured by change in Edmonton Revised Symptom Assessment Scale (ESAS-r) from
enrollment to 6 months [28]. The Three-Item Loneliness
Scale comprises a three-by-three Likert scale, with
higher score indicating more loneliness. To maximize
validity of a three-item scale, we assessed each question
(lacking companionship, feeling left out, feeling isolated
from others) separately and did not sum the responses
for a total loneliness score.
The ESAS-r comprises nine common symptoms rated
in severity on an 11-point scale plus space to rate additional symptoms; higher scores indicate greater symptom burden. Studies of the older version of the same
scale (ESAS) have shown that a more general picture of
symptom severity can be gained by summing individual
symptom scores for a total symptom burden score, reported on a scale from 0 to 100. Total symptom burden
can therefore be assessed as absent (0), mild [1–30],
moderate (31–60), or severe (61–100), and clinical significance is previously defined as a total symptom score
of 31 or greater [29, 30]. For the purposes of this baseline analysis, we summed items to obtain a total symptom score but did not look at individual symptom
responses (e.g. pain).

Study protocol

Enrollment of patients is ongoing as our target sample
size is 1350 patients, but for this cohort occurred between April 2018 and April 3, 2020. Screening and enrollment take place seven days per week, 24 h per day.
Research assistants (RAs) check the ED and observation
unit electronic track boards to identify patients with
qualifying medical conditions, and then review the patients’ EHR to confirm inclusion criteria are met. RAs
then approach patients and conduct face-to-face interviews to confirm all eligibility criteria are met. RAs
complete written informed consent and Health Insurance Portability and Accountability Act authorization
and conduct a survey to gather baseline data. For
Spanish-speakers, a language-appropriate consent form
is used and either bilingual, certified study staff or noninvestigator, hospital-employed, trained interpreters assist in acquisition of informed consent. Once enrolled,
the coordinating site performs two-arm randomization
(outpatient specialty palliative care vs telephonic nursedelivered palliative care) stratified by site and illness type
(cancer vs. end-stage organ failure).
The central team ensures uniform application of the
methods across sites via an initial site visit, detailed
Standard Operating Procedures (SOPs), standardized
training of all new staff, as well as consistent re-training,
and practice of the study pitch via tele-conference with
central team members. Data collection, management
and randomization occur using in a central REDCap
database hosted at NYU School of Medicine to ensure
consistency [22, 23]. Additional details are highlighted in
the study protocol paper [21].
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Data analysis

We described baseline socio-demographic characteristics
and functional status for patients enrolled in the study
through April 2020. Means and standard deviations were
calculated for continuous variables, and frequencies and
percentages were calculated for categorical variables.
To assess the strength of the relationship of disease
condition and QOL as measured by the FACT-G, we
first used data visualization. We estimated a linear regression model to examine the importance of illness
group membership in predicting overall FACT-G score,
adjusting for age, education level, race, sex, immigrant
status, the presence of a caregiver, comorbid illness, and
hospital setting. All covariates were pre-determined a
priori and included in the model based on our belief that
they might be potential predictors of FACT-G scores.
Chi-square tests of independence and additional plots
were used to assess the strength of the relationship between illness group and the two secondary outcomes,
loneliness and symptom burden.
All analyses were conducted using R, Version 3.6.3 (R
Foundation for Statistical Computing).

Results
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regular assistance to the patient and is either a family
member or a close friend who lives with the patient fulltime [31].
Data Missingness

For the demographic data, missing data was largely limited to annual household income, where 17% (n = 83) of
the patients either did not know or declined to report it.
There were some other demographic items that patients
declined to report, including level of education (n = 15),
religious status (n = 11), ethnicity (n = 5), race (n = 4),
marital status (n = 4), functional status (n = 2), and birth
country (n = 1).
There was virtually no missing data for the baseline
survey data, where less than 1% (n = 5) of patients did
not provide sufficient data to calculate an overall FACTG score. Due to time constraints in the ED setting, two
patients did not complete any questions in the UCLA 3item loneliness scale, three additional patients declined
to answer the question ‘I have a lack of companionship’,
one patient declined to answer ‘I feel left out’, and one
declined to answer ‘I feel isolated from others’. Also due
to time constraints in the ED setting, one patient did not
complete any questions in the ESAS-r.

Participant characteristics

Patients recruited through April 3, 2020 were eligible for
inclusion. We identified 13,872 patients with advanced
illness criteria across 18 ED sites nationwide who were
assessed further for eligibility. Of those patients, 1138
(8%) met all inclusion and no exclusion criteria and were
eligible; 530 (47%) of those eligible were enrolled, and
519 were randomized (Fig. 1).
Ten patients were found to meet exclusion criteria
after enrollment and before randomization and were
never randomized. Nineteen of those randomized were
determined to be screen failures post-randomization,
and were excluded from the analysis. Thus, the baseline
analysis and tables comprise a total of 500 study
patients.
Participant demographics

Baseline demographic characteristics are listed in Table 1.
The cohort is 54% female, with a median age of 66 (IQR:
50 to 95) years, two-thirds white, 88% non-Hispanic,
89% United States-born, and 56% have at least some college education. Approximately three-quarters practice a
religious faith. Thirty-eight percent have an annual
household income of less than $25,000, and 32% are insured through Medicare only; 18% are dual eligible
Medicare/Medicaid.
Approximately one-third are married, half are private
home-dwellers, and about half (51%) require assistance
to care for themselves. Fifty percent have a primary family caregiver, which is defined as someone who provides

Baseline primary outcomes

Out of a possible overall FACT-G score of 108, our cohort of persons presenting to the ED with end-stage illness have an overall median FACT-G score of 63 (IQR:
11 to 107) indicating compromised QOL. The subgroup
of patients with advanced cancer have less compromised
QOL across all four domains (physical, emotional, social/family, and functional) as well as a less compromised total score compared to patients with end-stage
organ failure (Fig. 2). Those with end-stage organ failure
have a median score of 59 (11 to 107), while those with
cancer have a median score of 69 (12 to 106).
The linear regression model (Table 2) based on 475
patients with complete data suggests that illness type is
indeed associated with QOL after adjusting for age, education level, race, sex, immigrant status, the presence of
a caregiver, and hospital setting. On average, those with
end-stage organ failure have lower QOL compared to
those with advanced cancer, with an estimated difference
of 9.6 points (95% CI: 5.9, 13.3), and those with at least
two life-limiting illnesses have a further reduction of 7.4
points (95% CI: 2.4, 12.5). This estimated difference between cancer and end-stage organ failure in overall score
is consistent with the mean difference in Fig. 2. Older
adults on average report better QOL than those of younger age after adjusting for all other characteristics; for
each additional year of age, there is on average a 0.24
point increase (95% CI: 0.07, 0.41) in FACT-G score.
The parameter estimates for the remaining
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Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) Diagram

Baseline secondary outcomes

companionship). Patients with cancer appear to be more
likely to have mild symptom burden (37% vs 27%) and
less likely to have severe symptom burden compared
with end-stage organ failure patients (9% vs 17%) (Fig. 3
- Panel B).

Each of the three questions on the UCLA 3-item loneliness scale was examined separately (Fig. 3 - Panel A).
Ten percent of cancer patients often felt isolated, versus
25% of end-stage organ failure patients. Similar patterns
were seen for the other two loneliness items (9% versus
26% often felt left out; 13% versus 25% lacked

Discussion
This report demonstrates that the EMPallA randomized
controlled trial is enrolling a diverse sample of older
adults with advanced illness who present to the ED. In
the EMPallA trial cohort, 59% of patients identified as

characteristics were less conclusive. Overall, 8% of the
variability in the outcome is accounted for by the set of
covariates in our model.
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Table 1 Baseline Characteristics of Participants (Continued)

Variable

Totals (N = 500,
%)

Age (50–95)

67 (10) (mean, SD)

Sex
Female

270 (54)

Male

230 (46)

Illness*

Variable
Separated

Totals (N = 500,
%)
24 (5)

Divorced

77 (15)

Living with a partner

20 (4)

Residence type
Apartment, elevator

125 (25)

Cancer

206 (41)

Apartment, no elevator

79 (16)

End-stage renal disease

101 (20)

Private home with stairs

194 (39)

Chronic obstructive pulmonary disease

135 (27)

Private home with no stairs

81 (16)

Congestive heart failure

125 (25)

Other

21 (4)

Comorbid (two or more of above Illnesses)

Insurance Type (can have multiple)

Yes

63 (13)

Employer

49 (10)

No

437 (87)

Purchased

13 (3)

Medicare

158 (32)

Race (4 Refused)
White

294 (59)

Medicaid

65 (13)

Black

147 (29)

Veterans Affairs

3 (1)

Other

44 (9)

Other

18 (4)

Multiple races

11 (2)

Dual eligible Medicare/Medicaid

89 (18)

Dual eligible (any other than Medicare/
Medicaid)

105 (21)

Ethnicity (5 Refused)
Hispanic

54 (11)

Non-Hispanic

441 (88)

Functional Status (2 Refused)
Disabled

35 (7)

Requires considerable assistance

83 (17)

Requires occasional assistance

137 (27)

Cares for self, unable to do normal activity

107 (21)

Normal activity

136 (27)

Primary Language
English

489 (98)

Spanish

11 (2)

Income (30 Refused, 53 Don’t Know)
Less than $25 K

191 (38)

$25 K - $49,999 K

101 (20)

$50 K - $99,999 K

69 (14)

$100 K or more

56 (11)

Do not practice/believe

138 (28)

Catholic

119 (24)

Other

115 (23)

Protestant

96 (19)

Jewish

21 (4)

Born in US (1 Refused)
Yes

447 (89)

No

52 (10)

Has primary family caregiver
Yes

250 (50)

No

250 (50)

Hospital setting
Urban

346 (69)

Suburban

154 (31)

*Patients can have multiple illnesses

Education Level (1 missing, 15 Refused)
< High school degree

75 (15)

High school degree

127 (25)

Some college/AA degree

144 (29)

College degree or >

138 (28)

Marital Status (4 Refused, 1 Other)
Married

Religion (11 Refused)

180 (36)

Never married

111 (22)

Widow (er)

83 (17)

white and 11% identified as Hispanic or Latino. Female
participants made of 54% of the cohort. Thirty-two percent of study participants had Medicare only, and 18%
were dual-eligible for Medicare and Medicaid. Participants were distributed between the diseases of interest;
cancer was the most common diagnosis at 41% and
ESRD the least common at 20%. Notably, the EMPallA
trial includes patients with multiple chronic conditions,
whom are often excluded from randomized controlled
trials [33]. Thirteen percent of study participants met
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Fig. 2 Baseline Quality of Life of Participants

Table 2 Linear regression to examine the importance of illness
group membership in predicting FACT-G score [32].
Dependent variable:
Total FACT-G score
Age

0.24 (0.07, 0.41)

Some college or more

0.95 (−2.45, 4.35)

Has a caregiver

1.28 (−2.03, 4.58)

Suburban hospital setting

3.78 (−0.002, 7.57)

Non-white

1.84 (−1.96, 5.64)

Male

1.38 (−1.91, 4.67)

Foreign born

1.32 (−4.38, 7.01)

Not comorbid

7.42 (2.40, 12.45)

Has cancer

9.62 (5.90, 13.34)

Constant

49.71 (43.43, 55.98)

Observations

475

R2

0.10

Adjusted R2

0.08

Residual Std. Error

17.78 (df = 465)

F Statistic

5.58 (df = 9; 465)

eligibility criteria for two or more serious, life-limiting
illnesses, and we suspect that many more have multiple
conditions that are less severe. The demographics of the
patients in the EMPallA study are similar to those reported in 2017 by the Centers for Disease Control and
Prevention from a representative sample of ED visits in
the US [34].
In this large, multi-center randomized controlled trial
in ED patients, we observed important differences in
baseline QOL when stratifying by disease type and controlling for demographic variables. QOL was low for all
study participants, which is consistent with their advanced illness status and suggests they may particularly
benefit from palliative care interventions. When comparing illness types, patients with organ failure had worse
QOL on all FACT-G subscales and the overall FACT-G
score as compared with cancer patients. Additionally,
patients with organ failure had higher symptom burden
and more loneliness than cancer patients. One reason
this might be the case is that cancer patients presenting
to the ED have previously been healthy and are just
starting the rapid end-of-life decline in functional status,
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Fig. 3 Secondary Outcomes by Illness Type

whereas organ failure patients have experienced repeated
episodes of exacerbations and remissions [19]. Patients
with CHF and COPD have been shown to have more
hospital admissions and ED visits than cancer patients in
the last months of life, which could contribute to poorer
QOL [35]. Similarly, patients with ESRD tend to have
lower rates of advance care planning, higher treatment
intensity, and similarly high symptom burden in the last
year of life compared to cancer patients [36].
Our model also indicated that meeting inclusion criteria for multiple advanced illnesses was independently
associated with a poorer QOL. This is consistent with
prior studies; a meta-analysis of 74 studies showed that
an individual’s QOL decreases with each additional illness [37]. Additionally, we found that older age is associated with improved QOL. We are unsure about why this
is, but hypothesize it might be because patients who

have lived longer have likely experienced less serious illness during their lifetime.
To our knowledge, this is the first large, multicenter
trial enrolling older adults with multiple different advanced illnesses from the ED. While the distinct disease
trajectories of patients with cancer and end-stage organ
failure have been elucidated in other settings, this report
is unique in presenting a snapshot of the distinct trajectories at the time of an ED visit. The differences by illness type in QOL, symptom burden, and loneliness
seem to reflect the sudden deterioration of cancer patients at the end of life versus the undulating decline of
those with organ failure [19].
For older adults with serious illness presenting to
the ED, we have demonstrated that QOL, symptom
burden, and loneliness differ by illness type, suggesting that palliative care needs may differ by disease
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category as well [38]. For this reason, the subgroup
analyses by illness type in the final EMPallA analysis
will be important in determining how to interpret the
primary outcome of the study for patients of different
illness types and in designing future palliative care interventions that benefit particular disease types. Despite similar symptom burdens, illness experience, and
survival rates between advanced cancer and end-stage
organ failure, much of the attention directed toward
improving end-of-life care has focused on cancer patients [17, 35, 36, 39]. This report highlights the need
for more disease-specific research to improve patientcentered outcomes for those with end-stage organ
failure presenting to the ED. Additionally, since patients with multiple chronic conditions have particularly low QOL, future research should focus on
developing palliative care interventions to target these
patients, as well as screening and referral protocols to
be used by ED providers.
A strength of our study is that it is enrolling a large
national cohort with a rich set of baseline demographic
variables and patient-reported outcome measures. Its inclusive inclusion criteria facilitate recruitment of diverse
patients. Additionally, by including patients with both
cancer and end-stage organ failure, palliative care interventions can be assessed in unique disease processes.
Nevertheless, our study has various limitations. Only
about 50% of patients who are approached are willing to
enroll in the study. Patient refusal or failure to follow up
could result in a non-response bias, where enrolled patients are those open to trying palliative care. Additionally, this study is limited to four specific diseases, only
recruits English- and Spanish-speaking patients, and is
conducted within the US, meaning it may not be
generalizable to patients outside these demographics. Finally, all outcomes are self-reported rather than objectively measured. However, patient-reported outcomes are
commonly used in palliative care and are validated to
measure QOL and symptom burden [24, 25].

Conclusions
The EMPallA trial is enrolling a diverse sample of ED
patients. The lower QOL, increased symptom burden,
and increased loneliness found in end-stage organ failure
patients versus cancer patients demonstrates how distinct disease trajectories manifest in the ED.
Abbreviations
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